Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Sell
47
SUPN Quote, Financials, Valuation and Earnings
Last price:
$32.13
Seasonality move
:
11.43%
Day range:
$31.97 - $32.90
52-week range:
$25.53 - $40.28
Dividend yield:
0%
P/E ratio:
24.32x
P/S ratio:
2.72x
P/B ratio:
1.73x
Volume:
2.3M
Avg. volume:
762.8K
1-year change:
-8.59%
Market cap:
$1.8B
Revenue:
$661.8M
EPS (TTM):
$1.32
Analysts' Opinion
-
Consensus RatingSupernus Pharmaceuticals has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $38.80, Supernus Pharmaceuticals has an estimated upside of 20.68% from its current price of $32.15.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $36.00 representing 100% downside risk from its current price of $32.15.
Fair Value
-
According to the consensus of 5 analysts, Supernus Pharmaceuticals has 20.68% upside to fair value with a price target of $38.80 per share.
SUPN vs. S&P 500
-
Over the past 5 trading days, Supernus Pharmaceuticals has overperformed the S&P 500 by 2.33% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Supernus Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Supernus Pharmaceuticals has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Supernus Pharmaceuticals reported revenues of $174.2M.
Earnings Growth
-
Supernus Pharmaceuticals has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Supernus Pharmaceuticals reported earnings per share of $0.27.
Enterprise value:
1.3B
EV / Invested capital:
1.29x
Price / LTM sales:
2.72x
EV / EBIT:
13.70x
EV / Revenue:
2.03x
PEG ratio (5yr expected):
0.19x
EV / Free cash flow:
7.83x
Price / Operating cash flow:
10.51x
Enterprise value / EBITDA:
7.52x
Gross Profit (TTM):
$583.9M
Return On Assets:
5.59%
Net Income Margin (TTM):
11.16%
Return On Equity:
7.61%
Return On Invested Capital:
7.61%
Operating Margin:
12.5%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $667.2M | $607.5M | $661.8M | $164.3M | $174.2M | |
| Gross Profit | $580M | $523.7M | $583.9M | $144.7M | $148.1M | |
| Operating Income | $45.6M | $13.4M | $75.6M | $19M | $21.8M | |
| EBITDA | $153.4M | $90M | $178.3M | $22.7M | $45.2M | |
| Diluted EPS | $1.03 | -$0.00 | $1.32 | $0.02 | $0.27 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $630.4M | $601.6M | $734.2M | $493.1M | $686.1M | |
| Total Assets | $1.5B | $1.7B | $1.7B | $1.3B | $1.4B | |
| Current Liabilities | $245.1M | $315.4M | $688M | $290.2M | $292.4M | |
| Total Liabilities | $759.2M | $873.3M | $816.3M | $356.2M | $332.3M | |
| Total Equity | $744.9M | $815.9M | $886.2M | $921.5M | $1B | |
| Total Debt | $361.8M | $379.3M | $402M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $116.8M | $111.1M | $172M | $45M | $44.4M | |
| Cash From Investing | -$216.7M | $268.7M | -$189.9M | -$66M | -$12.6M | |
| Cash From Financing | -$10.5M | -$397.9M | $12.2M | $1.1M | $5.9M | |
| Free Cash Flow | $116.4M | $110.5M | $171.2M | $45M | $44.2M | |
SUPN
Sector
Market Cap
$1.8B
$39.2M
Price % of 52-Week High
79.82%
45.93%
Dividend Yield
0%
0%
Shareholder Yield
-0.74%
-0.81%
1-Year Price Total Return
-8.59%
-38.63%
Beta (5-Year)
0.835
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$31.84
200-day SMA
Sell
Level
$33.22
Bollinger Bands (100)
Sell
Level
33.53 - 38.31
Chaikin Money Flow
Buy
Level
38.4M
20-day SMA
Buy
Level
$32.11
Relative Strength Index (RSI14)
Sell
Level
41.66
ADX Line
Sell
Level
34.09
Williams %R
Neutral
Level
-36.4486
50-day SMA
Sell
Level
$35.83
MACD (12, 26)
Sell
Level
-1.11
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
97.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.2736)
Buy
CA Score
(Annual)
Level (1.1653)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-3.0171)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Stock Forecast FAQ
In the current month, SUPN has received 2 Buy ratings 3 Hold ratings, and 0 Sell ratings. The SUPN average analyst price target in the past 3 months is $38.80.
-
Where Will Supernus Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Supernus Pharmaceuticals share price will rise to $38.80 per share over the next 12 months.
-
What Do Analysts Say About Supernus Pharmaceuticals?
Analysts are divided on their view about Supernus Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Supernus Pharmaceuticals is a Sell and believe this share price will drop from its current level to $36.00.
-
What Is Supernus Pharmaceuticals's Price Target?
The price target for Supernus Pharmaceuticals over the next 1-year time period is forecast to be $38.80 according to 5 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is SUPN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Supernus Pharmaceuticals is a Hold. 3 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of SUPN?
You can purchase shares of Supernus Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Supernus Pharmaceuticals shares.
-
What Is The Supernus Pharmaceuticals Share Price Today?
Supernus Pharmaceuticals was last trading at $32.13 per share. This represents the most recent stock quote for Supernus Pharmaceuticals. Yesterday, Supernus Pharmaceuticals closed at $32.15 per share.
-
How To Buy Supernus Pharmaceuticals Stock Online?
In order to purchase Supernus Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
